1
|
Petrov SA, Machulkin AE, Uspenskaya AA, Zyk NY, Nimenko EA, Garanina AS, Petrov RA, Polshakov VI, Grishin YK, Roznyatovsky VA, Zyk NV, Majouga AG, Beloglazkina EK. Polypeptide-Based Molecular Platform and Its Docetaxel/Sulfo-Cy5-Containing Conjugate for Targeted Delivery to Prostate Specific Membrane Antigen. Molecules 2020; 25:molecules25245784. [PMID: 33302417 PMCID: PMC7762530 DOI: 10.3390/molecules25245784] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Revised: 12/03/2020] [Accepted: 12/06/2020] [Indexed: 01/29/2023] Open
Abstract
A strategy for stereoselective synthesis of molecular platform for targeted delivery of bimodal therapeutic or theranostic agents to the prostate-specific membrane antigen (PSMA) receptor was developed. The proposed platform contains a urea-based, PSMA-targeting Glu-Urea-Lys (EuK) fragment as a vector moiety and tripeptide linker with terminal amide and azide groups for subsequent addition of two different therapeutic and diagnostic agents. The optimal method for this molecular platform synthesis includes (a) solid-phase assembly of the polypeptide linker, (b) coupling of this linker with the vector fragment, (c) attachment of 3-aminopropylazide, and (d) amide and carboxylic groups deprotection. A bimodal theranostic conjugate of the proposed platform with a cytostatic drug (docetaxel) and a fluorescent label (Sulfo-Cy5) was synthesized to demonstrate its possible sequential conjugation with different functional molecules.
Collapse
Affiliation(s)
- Stanislav A. Petrov
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Aleksei E. Machulkin
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
- Laboratory of Biomedical Nanomaterials, National University of Science and Technology MISiS, Leninskiy pr., 4, 119049 Moscow, Russia
| | - Anastasia A. Uspenskaya
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Nikolay Y. Zyk
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Ekaterina A. Nimenko
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Anastasia S. Garanina
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
- Laboratory of Biomedical Nanomaterials, National University of Science and Technology MISiS, Leninskiy pr., 4, 119049 Moscow, Russia
| | - Rostislav A. Petrov
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Vladimir I. Polshakov
- Faculty of Fundamental Medicine, Lomonosov Moscow State University, Lomonosovsky Ave., 27-1, 119991 Moscow, Russia;
| | - Yuri K. Grishin
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Vitaly A. Roznyatovsky
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Nikolay V. Zyk
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
| | - Alexander G. Majouga
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
- Laboratory of Biomedical Nanomaterials, National University of Science and Technology MISiS, Leninskiy pr., 4, 119049 Moscow, Russia
- Mendeleev University of Chemical Technology of Russia, Miusskaya sq. 9, 125947 Moscow, Russia
| | - Elena K. Beloglazkina
- Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory, 1-3, 119991 Moscow, Russia; (S.A.P.); (A.E.M.); (A.A.U.); (N.Y.Z.); (E.A.N.); (A.S.G.); (R.A.P.); (Y.K.G.); (V.A.R.); (N.V.Z.); (A.G.M.)
- Correspondence:
| |
Collapse
|
2
|
Lai YH, Chiang CS, Hsu CH, Cheng HW, Chen SY. Development and Characterization of a Fucoidan-Based Drug Delivery System by Using Hydrophilic Anticancer Polysaccharides to Simultaneously Deliver Hydrophobic Anticancer Drugs. Biomolecules 2020; 10:E970. [PMID: 32605162 PMCID: PMC7408464 DOI: 10.3390/biom10070970] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 06/25/2020] [Accepted: 06/26/2020] [Indexed: 12/12/2022] Open
Abstract
Fucoidan, a natural sulfated polysaccharide, which can activate the immune response and lessen adverse effects, is expected to be an adjuvant agent in combination with chemotherapy. Using natural hydrophilic anticancer polysaccharides to simultaneously encapsulate hydrophobic anticancer drugs is feasible, and a reduced side effect can be achieved to amplify the therapeutic efficacy. In this study, a novel type of fucoidan-PLGA nanocarrier (FPN-DTX) was developed for the encapsulation of the hydrophobic anticancer drug, docetaxel (DTX), as a drug delivery system. From the comparison between FPN-DTX and the PLGA particles without fucoidan (PLGA-DTX), FPNs-DTX with fucoidan were highly stable with smaller sizes and dispersed well without aggregations in an aqueous environment. The drug loading and release can be further modified by modulating relative ratios of Fucoidan (Fu) to PLGA. The (FPN 3-DTX) nanoparticles with a 10:3 ratio of Fu:PLGA displayed uniform particle size with higher encapsulation efficiency than PLGA NPs and sustained drug release ability. The biocompatible fucoidan-PLGA nanoparticles displayed low cytotoxicity without drug loading after incubation with MDA-MB-231 triple-negative breast cancer cells. Despite lower cellular uptake than that of PLGA-DTX due to a higher degree of negative zeta potential and hydrophilicity, FPN 3-DTX effectively exerted better anticancer ability, so FPN 3-DTX can serve as a competent drug delivery system.
Collapse
Affiliation(s)
- Yen-Ho Lai
- Department of Materials Science and Engineering, National Chiao Tung University, Hsinchu 30010, Taiwan; (Y.-H.L.); (C.-H.H.); (H.-W.C.)
| | - Chih-Sheng Chiang
- Cell Therapy Center, China Medical University Hospital, Taichung 40454, Taiwan;
| | - Chin-Hao Hsu
- Department of Materials Science and Engineering, National Chiao Tung University, Hsinchu 30010, Taiwan; (Y.-H.L.); (C.-H.H.); (H.-W.C.)
| | - Hung-Wei Cheng
- Department of Materials Science and Engineering, National Chiao Tung University, Hsinchu 30010, Taiwan; (Y.-H.L.); (C.-H.H.); (H.-W.C.)
| | - San-Yuan Chen
- Department of Materials Science and Engineering, National Chiao Tung University, Hsinchu 30010, Taiwan; (Y.-H.L.); (C.-H.H.); (H.-W.C.)
- Frontier Research Centre on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan
- School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
- Graduate Institute of Biomedical Science, China Medical University, Taichung 40454, Taiwan
| |
Collapse
|
3
|
Guerreiro DD, de Lima LF, de Sá NAR, Tetaping GM, Alves BG, Lobo CH, Deusdênia Loiola O, Smitz J, de Figueiredo JR, Ribeiro Rodrigues AP. In vitro study of Withanolide D toxicity on goat preantral follicles and its effects on the cell cycle. Reprod Toxicol 2019; 84:18-25. [DOI: 10.1016/j.reprotox.2018.12.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 12/15/2018] [Accepted: 12/19/2018] [Indexed: 10/27/2022]
|
4
|
Mbatchi LC, Schmitt A, Thomas F, Cazaubon Y, Robert J, Lumbroso S, Brouillet JP, Pourquier P, Chatelut E, Boyer JC, Evrard A. Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics 2015; 16:1439-50. [DOI: 10.2217/pgs.15.84] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: The goal of our study was to assess the impact of patients’ genetic background on their sensitivity to carboplatin/paclitaxel hematotoxicity. Patients & methods: Parameters describing sensitivity to neutropenia and to thrombocytopenia of 201 patients were extracted from a previous pharmacokinetic/pharmacodynamics analysis, in order to assess their association with 52 candidates SNPs in 18 genes. Results: Carriers of a T allele of SLCO1B3-rs4149117 were 19% less sensitive to thrombocytopenia than the homozygotes for the G allele (p = 0.00279). Carriers of two copies of the ATG haplotypes of NR1I2-rs1523130, rs3814055 and rs1523127 were 19% less sensitive to thrombocytopenia than those harboring other haplotypes (p = 0.025). Conclusion: Our results revealed the importance of SLCO1B3 and NR1I2 in the sensitivity to carboplatin/paclitaxel thrombocytopenia.
Collapse
Affiliation(s)
- Litaty Céphanoée Mbatchi
- Laboratoire de biochimie, Centre Hospitalier Universitaire (CHU) of Nîmes, Hôpital Carémeau, Nîmes, France
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, INSERM, U1194 France
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Montpellier, Montpellier, France
| | - Antonin Schmitt
- EA4553 Institut Claudius-Regaud, and Université Paul-Sabatier, Toulouse, France
| | - Fabienne Thomas
- EA4553 Institut Claudius-Regaud, and Université Paul-Sabatier, Toulouse, France
| | - Yoann Cazaubon
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Montpellier, Montpellier, France
| | - Jacques Robert
- INSERM U916, Institut Bergonié, Université de Bordeaux, France
| | - Serge Lumbroso
- Laboratoire de biochimie, Centre Hospitalier Universitaire (CHU) of Nîmes, Hôpital Carémeau, Nîmes, France
| | - Jean-Paul Brouillet
- Laboratoire de biochimie, Centre Hospitalier Universitaire (CHU) of Nîmes, Hôpital Carémeau, Nîmes, France
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, INSERM, U1194 France
| | - Philippe Pourquier
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, INSERM, U1194 France
| | - Etienne Chatelut
- EA4553 Institut Claudius-Regaud, and Université Paul-Sabatier, Toulouse, France
| | - Jean-Christophe Boyer
- Laboratoire de biochimie, Centre Hospitalier Universitaire (CHU) of Nîmes, Hôpital Carémeau, Nîmes, France
| | - Alexandre Evrard
- Laboratoire de biochimie, Centre Hospitalier Universitaire (CHU) of Nîmes, Hôpital Carémeau, Nîmes, France
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, INSERM, U1194 France
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Université de Montpellier, Montpellier, France
| |
Collapse
|
5
|
Hopper-Borge EA, Churchill T, Paulose C, Nicolas E, Jacobs JD, Ngo O, Kuang Y, Grinberg A, Westphal H, Chen ZS, Klein-Szanto AJ, Belinsky MG, Kruh GD. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 2011; 71:3649-57. [PMID: 21576088 DOI: 10.1158/0008-5472.can-10-3623] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Recently, we reported that the ATP-binding cassette transporter 10 (ABCC10), also known as multidrug resistance protein 7 (MRP7), is able to confer resistance to a variety of anticancer agents, including taxanes. However, the in vivo functions of the pump have not been determined to any extent. In this study, we generated and analyzed Abcc10(-/-) mice to investigate the ability of Abcc10 to function as an endogenous resistance factor. Mouse embryo fibroblasts derived from Abcc10(-/-) mice were hypersensitive to docetaxel, paclitaxel, vincristine, and cytarabine (Ara-C) and exhibited increased cellular drug accumulation, relative to wild-type controls. Abcc10(-/-) null mice treated with paclitaxel exhibited increased lethality associated with neutropenia and marked bone marrow toxicity. In addition, toxicity in spleen and thymus was evident. These findings indicate that Abcc10 is dispensable for health and viability and that it is an endogenous resistance factor for taxanes, other natural product agents, and nucleoside analogues. This is the first demonstration that an ATP-binding cassette transporter other than P-glycoprotein can affect in vivo tissue sensitivity toward taxanes.
Collapse
|
6
|
Takano M, Otani Y, Tanda M, Kawami M, Nagai J, Yumoto R. Paclitaxel-resistance Conferred by Altered Expression of Efflux and Influx Transporters for Paclitaxel in the Human Hepatoma Cell Line, HepG2. Drug Metab Pharmacokinet 2009; 24:418-27. [DOI: 10.2133/dmpk.24.418] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
7
|
Abstract
During recent years, it has become increasingly recognized that drug transporters play important roles in drug absorption and disposition. Organic anion transporting polypeptides (OATPs) are membrane transporters critically involved in the cellular uptake of drugs in tissues important for pharmacokinetics, such as the intestine, liver and kidneys. Recent advances in the pharmacogenomics of OATP1B1 have revealed that OATP transporters can play important roles in explaining interindividual variability in drug pharmacokinetics, and thus contribute to interindividual as well as interethnic variability in drug response. This article will provide an up-to-date review of human OATPs and their substrates, and a current compilation of their DNA sequence variations.
Collapse
Affiliation(s)
- Mikko Niemi
- University of Helsinki, Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, Helsinki, FIN-00029 HUS, Finland.
| |
Collapse
|